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Abstract
Extracellular vesicles (EVs) are promising natural nanocarriers for delivery of various types of 
therapeutics. Earlier engineered EV-based formulations for neurodegenerative diseases and cancer 
are reported. Herein, the use of macro-phage-derived EVs for brain delivery of a soluble lysosomal 
enzyme tripeptidyl peptidase-1, TPP1, to treat a lysosomal storage disorder, Neuronal Ceroid 
Lipo-fuscinoses 2 (CLN2) or Batten disease, is investigated. TPP1 is loaded into EVs using two 
methods: i) transfection of parental EV-producing macrophages with TPPI-encoding plasmid DNA 
(pDNA) or ii) incorporation therapeutic protein TPP1 into naive empty EVs. For the former 
approach, EVs released by pretransfected macrophages contain the active enzyme and TPPI-
encoding pDNA. To achieve high loading efficiency by the latter approach, sonication or 
permeabilization of EV membranes with saponin is utilized. Both methods provide proficient 
incorporation of functional TPP1 into EVs (EV-TPP1). EVs significantly increase stability of TPPI 
against protease degradation and provide efficient TPP1 delivery to target cells in in vitro model of 
CLN2. The majority ofEV-TPP1 (≈70%) is delivered to target organelles, lysosomes. Finally, a 
robust brain accumulation of EV carriers and increased lifespan is recorded in late-infantile 
neuronal ceroid lipofuscinosis (LINCL) mouse model following intraperitoneal administration of 
EV-TPP1.
Keywords
Batten disease; brain; drug delivery systems; EVs; lysosomal storage diseases
1. Introduction
The neuronal ceroid lipofuscinoses (NCLs) or Batten disease is a group of severe 
neurodegenerative diseases that primarily affect children and are characterized by the 
intracellular accumulation of storage material in neural tissues and progressive 
neurodegeneration. Morphologically, they are identified by loss of neurons, predominantly 
in the cerebellar cortices, and near-ubiquitous accumulation of NCL-specific lipopigments. 
Core symptoms of these conditions typically include epilepsy, cognitive decline and visual 
failure. CLN2 disease is one of a group of lysosomal storage disorders (LSDs) that results 
from mutations in the TPP1 gene that cause an insufficiency or complete lack of the soluble 
lysosomal enzyme tripeptidyl peptidase-1 (TPP1). Without functional TPP1, neurons 
develop inclusions of abnormal storage material; the retina and central nervous system 
(CNS) undergo progressive degeneration[1] resulting in loss of neurological functions and 
vision.[2] Thus, the successful delivery of functional TPP1 to CNS is of great importance.
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One of the major reasons for the failure of current therapeutic agents in treating 
neurodegenerative disorders is the existence of multiple biological barriers that prohibit 
effective drug delivery to target cells. In particular, the blood brain barrier (BBB) remains a 
seemingly insurmountable obstacle to the routine use of systemically administered 
macromolecules—including TPP1. In this regard, recently emerged field of nanotechnology, 
and specifically development of different nanoformulations that may improve drug transport 
across the BBB attracted significant efforts of the research community.[3,4] Regrettably, 
these nanoparticles are rapidly cleared from the bloodstream by mononuclear phagocyte 
system (MPS).[5] Thus, there is an unmet clinical need to develop new drug delivery systems 
for treatment of different neurodegenerative disorders, and in particular, lysosomal storage 
diseases.[6,7]
To circumvent this problem, we propose using EVs as bio-compatible nanocarriers for 
delivery therapeutic material. EVs are naturally occurring biological vesicles in the size 
range of 60–500 nm that are known to specialize in cell–cell communication and therefore 
can provide unprecedented opportunities for delivering drugs to target cells. Furthermore, 
we suggest to utilize EVs derived from inflammatory-response cells, monocytes and 
macrophages, as drug delivery vehicles. It was reported that besides intrinsic neuronal 
defects, most LSDs patients show signs of neurodegeneration and brain inflammation.[8] The 
development of lysosomal inclusions results in microglial and astrocyte activation that is a 
hallmark of many LSDs. The inflammatory process affects the CNS, which often precedes 
and predicts regions where eventual neuron loss will occur. This provides the opportunity for 
site-specific delivery of therapeutic enzymes using inflammatory response cell-based 
platform, specifically, macrophage-derived EVs.
There is a growing interest in the use of EVs as nanocarriers; EVs were suggested as drug 
delivery vehicles for different small molecular weight therapeutics, such as an anti-
inflammatory agent, cur cumin, [9,10] or anticancer agents, doxorubicin[11,12] and paclitaxel.
[13–15] Moreover, EVs were harnessed for systemic delivery of exogenous nucleic acids 
across the biological barriers,[16–25] as well as adeno-associated viral vectors[26] and 
superparamagnetic iron oxide nanoparticles (SPIONS).[27] The incorporation of therapeutic 
agents into EVs increased the circulation time, preserved drug therapeutic activity, and 
improved their transport to the disease site. Furthermore, several reports indicate that EVs 
may improve pharmacokinetics and preserve activity of incorporated therapeutics. 
Furthermore, EVs have low immunogenicity due to the expression of CD47 receptor[12,28,29] 
that interacts with signal regulatory protein α (SIRPα) to produce a “don’t eat me” signal in 
phagocytes.[30,31] Finally, EVs can exert unique biological activity reflective of their origin. 
Thus, macrophage-derived EVs may preferentially interact with inflamed tissues and 
accomplish targeted delivery of therapeutics to the disease site. These exceptional features 
make EVs an attractive option for use as a drug delivery vehicle for Batten disease 
treatment, and should work in concert to dramatically improve the therapeutic efficacy of 
current treatment strategies utilizing TPP1.
We demonstrated earlier that macrophages pretransfected with catalase-, or glial cell line-
derived neurotrophic factor (GDNF)-encoding plasmid DNA (pDNA) ex vivo, release EVs 
with the encoded therapeutic protein, and improve transport of the drug to target cells of 
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neurovascular unit.[32–34] This resulted in significant therapeutic effects in mouse models of 
Parkinson’s disease (PD) and lipopolysaccharide (LPS)-induced encephalitis. We also 
reported that naïve macrophage-derived EVs can be loaded with therapeutic proteins, 
catalase or brain-derived neurotrophic factor (BDNF), ex vivo, and deliver their therapeutic 
payload to the brain resulting in the increased neuronal survival in different models of 
neurodegenerative disorders.[35,36]
Herein, we developed a novel biomimetic EV-based delivery system capable of TPP1 
transfer to the CNS. TPP1 was incorporated into macrophage-derived EVs by transfection of 
parental cells with TPP1-encoding pDNA (EV-TPP1-t), or loading of therapeutic protein, 
TPP1, into naïve (empty) EVs (EV-TPP1-l). The last approach utilized the permeabilization 
of EVs membranes with saponin, or sonication in the presence of TPP1. The obtained EV-
TPP1 formulations were evaluated for morphology, drug loading efficiency, TPP1 enzymatic 
activity, and stability. As expected, EVs provided a potent protection of TPP1 against 
protease degradation, and efficient transport of functional enzyme to target cells in in vitro 
model of CLN2. Furthermore, prolonged brain accumulation of EVs was demonstrated in 
mouse model of Batten disease, LINCL mice, in which CLN2 is disrupted by gene targeting.
[37] Importantly, treatment of LINCL mice with EV-based formulations of TPP1 
significantly increased their lifespan. We suggest that EVs secreted by immunocytes offer 
distinct advantages that uniquely position them as natural biocompartible and highly 
effective drug nanocarriers for systemic delivery of the lysosomal enzyme, TPP1, to the 
brain to treat NCLs.
2. Results and Discussion
2.1. EVs Secreted by Pretransfected Macrophages Contain Functional TPP1 and TPP1-
Encoding DNA
In one approach, TPP1-transfected EVs (EV-TPP1-t) were produced by transfection of IC21 
macrophages with TPP1-encoding pDNA, followed by isolation of EVs from the 
conditioned media. The optimal transfection conditions that provide for high levels and 
duration of therapeutic protein expression in macrophages[32] were used. First, we assessed 
the TPP1 levels in cell lysates and EVs at different time points using ELISA (Figure 1A). 
Similar to our previous reports regarding macrophages transfected with catalase- and 
GDNF-encoding pDNA,[32,34] the optimal time for highest TPP1 expression levels in cells 
and EVs was between second and fifth day after transfection (Figure 1A). Next, the TPP1 
enzymatic activity was measured with a TPP1 substrate, AF-AMC (ala-ala-pheny-
lalanine-7-amido-4-methylcoumarin) (Figure 1B). In this assay the maximal TPP1 activity 
in cells was observed at day 4 and 5. Based on the activity measurements and the particle 
number quantification by Nanoparticle Tracking Analysis (NTA) at day 5, 1011 EVs 
contained ≈10 μg of active TPP1, while the enzyme activity in nontransfected EVs was 
about one order of magnitude less. Interestingly, according to NTA, the average size of EVs 
isolated from TPP1-transfected macrophages was slightly greater (133.8 ± 4.1 nm) than that 
of EVs released from nontransfected parental cells (106.3 ± 9.3 nm) at the same time point 
(day 5). The TPP1 in EVs displayed increased stability against protease degradation 
compared to the free enzyme (Figure 1C). Thus, the TPP1 enzymatic activity was preserved 
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for at least 25 h upon the treatment of EV-TPP1-t with the mixture pronases from 
Streptomyces Griseus, compared to TPP1 alone that was significantly inactivated by this 
time point (Figure 1C). EV-TPP1-t retained the round morphology as demonstrated by AFM 
(Figure 1D).
Previous reports suggested that EVs released by catalase-and GDNF-transfected 
macrophages contained pDNA and mRNA encoding the respective proteins.[32,34] 
Therefore, we examined by quantitative real-time PCR (qPCR), whether the TP P1-
transfected macrophages can also release EVs with nucleic acids encoding TPP1 (Figure 
1E). As expected, TPP1 pDNA was detected in the EVs isolated from TPP1-transfected 
macrophages, but not in the control EVs released by empty-transfected cells (cont. EVs). 
According to the obtained calibration curve (Figure S1, Supporting Information), one 
million EVs carried ≈1955 copies or 1 × 10–5 ng of TPPl-encoding pDNA. Noteworthy, no 
TPP1-encoding mRNA was detected in EVs released by either TPP1- or empty-transfected 
macrophages by RT-PCR, although significant levels were found in the control HeLa cell as 
a positive control (Figure S2, Supporting Information).
2.2. Loading Naïve EVs with TPP1 Ex Vitro
In another approach, TPP1 protein was loaded into naïve macrophage-derived EVs. Two 
different loading protocols were used to cause disruption/healing of EVs membranes during 
incubation with TPP1: a) sonication in water bath, or b) permeabilization with saponin. The 
TPP1 loaded EVs (EV-TPP1-l) were purified from nonincorporated enzyme by gel-filtration 
chromatography (Figure S3, Supporting Information). Based on NTA, EV-TPP1-l were 
slightly larger than the naïve EVs (Figure 2A), but retained the round morphology as 
demonstrated by AFM (Figure 2B). Catalytically active TPP1 was efficiently incorporated 
into EVs in both procedures, albeit sonication produced slightly better results than the 
saponin permeabilization, as measured by the enzyme activity assay (Figure 2A). Overall, 
1011 EVs loaded by sonication contained ≈70 μg TPP1, while EVs loaded by saponin 
permeabilization contained ≈50 μg TPP1 by enzymatic activity. This is respectively, ≈7- and 
~5-times more than the TPP1 content determined in EV-TPP1-t isolated from transfected 
cells. Noteworthy, TPP1-loaded formulations showed presence of proteins that are specific 
for EVs: CD63, TSG101, and HSP90, according to western blot analysis (Figure S4, 
Supporting Information).
The enzyme was slowly released from EV-TPP1-l for over 24 h upon dialysis using 
membranes with a cutoff 2000 kDa (Figure 2C). Furthermore, the incorporation of the 
enzyme into EVs led to TPP1 stabilization against proteases digestion (Figure 2D), as well 
as considerable increase in the enzyme stability upon storage. Specifically, EV-TPP1-l 
retained at least ≈40% activity in water solution at 4 °C for over a month, while the free 
TPP1 was completely inactivated during this time (Figure S5, Supporting Information).
2.3. EVs Facilitate Active TPP1 Transport into CLN2 Cells
To exert therapeutic activity, TPP1 needs to be delivered to the lysosomes of the cells. This 
can be facilitated in the format of EVs that display at their surface tetraspanins and integrins 
enhancing their cellular attachment and accumulation.[38–40] In these studies, we used CLN2 
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cells that are deficient in TPP1 enzyme, as an in vitro model representative of enzyme 
deficiency in Batten disease. These cells were exposed to either EV-TPP1-t or EV-TPP1-l 
and the levels of TPP1 were determined in the lysates as presented in Figure 3. The TPP1 
levels in CLN2 cells treated with EV-TPP1-t at various time points were significantly higher 
than those for untreated cells, although not significantly different from the cells treated by 
“empty” EVs from macrophages transfected with GDNF-encoding pDNA (Figure 3A). We 
posit that the empty EVs from IC21 macrophages have some endogenous TPP1 that was 
thereby delivered to CLN2 cells exposed to these EVs. This is consistent with 
spectrophotometry measurements indicating very low, but detectable TPP1 enzymatic 
activity in naïve EVs released by IC21 macrophages (Figure 2A). Interestingly, the TPP1 
levels in the EV-treated CLN2 cells decreased over time (Figure 3A) suggesting that the 
enzyme was degraded over several days. Therefore, we used a shorter exposure time point 
for the EV-TPP1-l (loaded using sonication or saponin permeabilization methods) that 
contained greater amount of TPP1 than EV-TPP1-t. In this case, CLN2 cells treated with 
EV-TPP1-l displayed much higher levels of TPP1 protein and enzyme activity than either 
untreated cells, or cells treated with empty EVs containing some endogenous TPP1 (Figure 
3B,C). Overall, EVs loaded with TPP1 protein delivered more enzyme to CLN2 cells than 
the EVs isolated from TPP1-transfected macrophages. Consistent with the loading results, 
the EV-TPP1-l loaded by sonication delivered 1.5 times more active TPP1 than the EV-
TPP1-l loaded by saponin permeabilization.
To address the intracellular localization of the EVs after delivery to neurons we performed, 
confocal studies in PC12 neuronal cells (Figure 4). In the described above experiments that 
were focused on TPP1 levels in target cells, we utilized deficient in the neuronal ceroid-
lipofuscinoses CLN2 cells that originated from human skin CLN2 fibroblasts. Low basic 
levels of TPP1 in these cells were crucial for assessing EV-mediated TPP1 delivery. 
However, to study intracellular distribution of EVs nanocarriers, and targeting lysosomal 
compartments, we consider that neuronal P12 cells would more accurately represent target 
neurons than fibroblast cells. Therefore, we used neuronal PC12 cells for intracellular 
localization studies. These studies revealed that the EVs following internalization into cells 
are predominantly localized in the lysosomal compartments. Specifically, after 1 and 4 h 
incubation of fluorescently labeled EVs with the PC12 cells, 74.2 ± 15.2% and 68.4 ± 16.7% 
EVs, respectively, were colocalized with the lysosomes (Figure 4A,B). This suggests that 
EVs are suitable vehicles for TPP1 delivery to lysosomes in neurons that are the presumable 
target for the therapeutic delivery of the TPP1. Noteworthy, similar targeting of lysosomal 
compartments was also found in CLN2 cells (Figure S6, Supporting Information).
2.4. Brain Accumulation of EVs in In Vivo Model of Batten Disease
To examine the ability of EVs to reach the brain tissues and deliver their payload, infrared 
spectroscopy (IVIS) studies were conducted in two months old LINCL mice. Specifically, 
macrophage-derived EVs were labeled with near-infrared lipophilic fluorescent dye DiR, 
and administered i.p. to LINCL mice (Figure 5). Fluorescent and light images of dorsal 
planes of the injected animals taken at various times showed significant accumulation of 
EVs in the brain (Figure 5A). Quantitative analysis of the in vivo imaging indicated that 
maximal brain accumulation of EVs was at 72 h. EVs were slowly cleared from the brain for 
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over 3 weeks (Figure 5B) that was confirmed by the postmortem imaging of main organs 
(Figure 5C). The same pattern was showed for TPP1-loaded EVs (Figure S7, Supporting 
Information). Noteworthy, at the endpoint, the animals were sacrificed and perfused before 
the organs imaging to remove any blood contents from them. As expected for i.p. 
administration, the highest EVs accumulation was detected in the liver, spleen, and lungs of 
CLN2 mice (Figure 5D). Fluorescent and light images of ventral planes of the injected 
animals taken at various times are presented on Figure S8 (Supporting Information).
Using live imaging does not allow distinguishing between EVs that are present in the blood 
stream or in the brain parenchyma. To eliminate this factor, LINCL mice were injected with 
fluorescently labeled EVs, then sacrificed and perfused according to standard protocol to 
eliminate EVs in the blood stream. The accumulation of EVs in the brain was evaluated by 
confocal microscopy. Furthermore, the age-related changes in brain accumulation of EVs 
carriers were examined. 1 week old and 2 months old animals were injected with DiD-
labeled EVs (red) through intraperitoneal (i.p.) route (Figure S9,Supporting Information). 
The early treatment of 1 week old animals (Figure S9A, Supporting Information) resulted in 
a greater amount of EVs in the brain, compared to the two months old mice (Figure S9B, 
Supporting Information). No fluorescence was found in control mice injected with saline 
(Figure S9C, Supporting Information).
Next, we compared the brain accumulation of DiD-labeled EVs and the same amount of 
DiD-labeled liposomes in 1 week old LINCL mice (Figure 6). Mice were sacrificed at 4 and 
24 h following i.p. injections and perfused to wash out possible contamination with 
nanocarriers in the blood. Confocal images revealed a significant amount of EVs throughout 
the brain tissues (Figure 6A), and low, if any, liposomes at these time points (Figure 6B). 
Finally, we investigated brain accumulation of fluorescently labeled Alexa 555-TPP1, which 
was loaded into EVs by sonication (Figure S10, Supporting Information). EV-Alexa 555-
TPP1 was injected into LINCL mice through i.p. route, mice were sacrificed at 24 h 
following injections, perfused, and brain slides were examined by confocal microscopy. 
LINCL mice injected with TPP1 alone were used as controls. In agreement with the EVs 
distribution pattern (Figure 6), significant fluorescence of Alexa 555-TPP1-EVs was 
detected in the brain of 1 week old and two months old animals (Figure S10A,B, 
respectively, Supporting Information). In contrast, low if any TPP1 fluorescence was 
detected, when the enzyme was administered alone (Figure S10C, Supporting Information).
2.5. Therapeutic Efficacy of EV-TPP1-l in In Vivo Model of Batten Disease
Based on the results of biodistribution studies, 1 week old LINCL mice were injected 
through intraperitoneal route with EV-TPP1-l formulation obtained by sonication in water 
bath (4.3 × 1012 particles mL−1, 150 μ.L per mouse, 15 mg kg−1) once per week, three 
weeks. LINCL mice and wild type (wt) mice treated with saline were used as positive and 
negative controls, respectively. LINCL mice injected with empty EVs were used in another 
control group. The survival was recorded for over three months (Figure 7). Administration 
of EV-TPP1-l formulation resulted in a significantly greater lifespan compared to control 
LINCL mice treated with saline. Treatment with naïve EVs produced subtle, but not 
Haney et al. Page 7













significant increase in life span of LINCL mice. This confirms the therapeutic efficacy of 
systemically administered EV-based TPP1 formulation.
Finally, systemic administration of EV-TPP1-l decreased neuroinflammation in LINCL mice 
compared to LINCL mice treated with saline (Figure 8). The obtained data indicate that 
LINCL mice treated with EV-TPP1-l has significantly lower astrocytosis (Figure 8B,D) 
compared to LINCL mice treated with saline (Figure 8A,D) that were near to the levels of 
healthy littermates (Figure 8C,D).
3. Conclusions
Batten disease is a lysosomal storage disease that typically begins in childhood. There are 
more than forty different lysosomal storage disorders (LSDs) resulting from deficiencies in 
lysosomal enzymes that lead to accumulation of various lysosomal substrates and 
subsequent neuronal death. In many cases the CNS is dramatically affected because of high 
vulnerability of neurons.[8] As such, targeted and efficient delivery of active enzymes across 
the BBB is of great importance for treatment of these conditions. Indeed, intracranial 
infusions of a therapeutically active lysosomal enzyme that is deficient in each LSD may 
provide protection of neurons. Unfortunately, this invasive procedure carries a high risk of 
adverse effects. Furthermore, a limited diffusion of the injected therapeutic enzyme through 
the brain tissues diminishes drug efficacy. In contrast, a systemic administration enables 
direct access to the BBB and uniform brain distribution through the brain capillaries. 
Regrettably, most potent therapeutic proteins failed to cross the BBB following systemic 
administration. In this respect, development of unconventional biocompatible and clinically 
applicable drug delivery systems may help to solve this challenging task. Thus, systemic 
coadministration of recombinant TPP1 along with a trans-acting peptide mediator 
(K16ApoE) was shown to significantly reduce brain lysosomal storage, increase lifespan and 
improve neurological function in LINCL mice.[41]
We report here a new EV-based technology for lysosomal enzyme, TPP1. Two different 
techniques for manufacturing EV-TPP1 were developed: transfection of parent cells, 
macrophages, with TPP1-encoding pDNA (EV-TPP1-t), and loading naïve EVs with TPP1 
enzyme ex vitro using sonication or saponin permeabilization (EV-TPP1-l). These methods 
were utilized earlier in our lab for loading different therapeutic proteins and low molecular 
chemotherapeutics.[13,14,32,34–36,42–44] The size of EV-TPP1-t and EV-TPP1-l was slightly 
increased by 30–35% compared to empty nanocarriers. Both methods secured manufacture 
of EV-TPP1 with active enzyme. For the first method, 1011 EVs carriers contained 
approximately 10 μg TPP1. Noteworthy, EV-TPP1-t also contained TPP1-encoding pDNA, 
suggesting that along with brain delivery of the enzyme, treatment with this formulation may 
result in transfection of brain tissues and de novo synthesis of TPP1. Markedly, no TPP1-
encoding mRNA was detected in EVs released by pretransfected macrophages, although we 
reported earlier the presence of GDNF- and catalase-encoding mRNA in EVs released by 
pretransfected with these therapeutic proteins plasmids macrophages. We speculate that it 
might be related to the specifics of these different proteins.
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Regarding the second approach, both sonication and saponin permeabilization provided 
substantial TPP1 loading into EVs, although sonication was slightly more efficient. We 
hypothesized that the extensive reformation and reshaping of EVs membranes upon 
sonication enabled TPP1 diffusion across relatively tight and highly structured lipid bilayers. 
In case of latter approach, saponin may selectively remove membrane-bound cholesterol of 
EVs, creating holes/pores in the EVs lipid bilayers and thus, promoting TPP1 loading. 
Interestingly, saponin permeabilization resulted in 1.5× times lesser loading efficiency 
compared to sonication method. Significantly, the incorporation of TPP1 in EVs ensued the 
efficient preservation of TPP1 enzymatic activity against proteases degradation, and 
prolonged sustained release over 24 h for both EV-TPP1-t and EV-TPP1-l formulations. 
Finally, these methods for drug incorporation into EVs may be specific not only for TPP1 
enzyme, but can be applied to other therapeutic and imaging agents.
Regarding the delivery of TPP1, this study demonstrated the ability of EVs to accumulate 
within target cells and specifically in lysosomal compartments. Thus, we demonstrated that 
both EV-TPP1-t and EV-TPP1-l delivered considerable amount of enzymatically active 
TPP1 in the in vitro model of Batten disease, CLN2 cells. As expected, EV-TPP1-l 
formulations, and especially, EVs loaded by sonication, provided the most efficient enzyme 
transport into target cells. Furthermore, confocal images revealed that ≈70% of fluorescently 
labeled EVs were accumulated in lysosomes in PC12 neural cells as well as CLN2 cells in 
vitro. Indeed, EVs are known to enter cells by endocytosis[45] and then accumulate in 
lysosomes, the target organelles for lysosomal storage disorders. This suggests that EVs 
carriers should be able to accomplish passive targeted delivery of TPP1 to lysosomes that is 
crucial for the treatment of LSDs. Further investigations will reveal mechanism and 
intracellular trafficking of various EVs formulations in target cells.
The main question remains, whether EVs carriers could deliver TPP1 to CNS. To address 
this issue, we investigated brain accumulation of fluorescently labeled EVs, as well as 
fluorescently labeled TPP1 in mouse model of Batten disease, LINCL mice. This is the 
model of early infant and childhood disease, therefore, we investigated two groups of 
LINCL mice, at early stages (1 week old), and late stages (2 months old) of the 
development. IVIS studies followed by confocal investigations demonstrated that EVs, as 
well as TPP1-loaded EVs efficiently accumulated in the mouse brain upon i.p. 
administration, and remained in the brain tissues for more than 3 weeks. Note-worthy, 
confocal images indicated that brain bioavailability for EVs and TPP1 is greater in younger 
1 week old animals, suggesting that the treatment of LINCL mice should be initiated at 
earlier stages of development. Consequently, i.p. injections of EV-TPP1-l of 1 week old 
LINCL mice significantly increased their lifespan compared to control LINCL mice treated 
with saline.
It is known that many LSDs are accompanied with neuro-inflammation, which leads to 
further neuronal damage and death.[18,46–49] We demonstrated earlier that macrophages,
[32–34,44] as well as macrophage-derived EVs target brain inflammation in animal models of 
PD and LPS-induced encephalitis.[35,36] The enhanced transport across the BBB was 
mediated by interactions between LFA-1 protein expressed on the membranes of 
macrophages and macrophage-derived EVs, and ICAM-1 receptor[36] that is known to be 
Haney et al. Page 9













overexpressed in the inflamed endothelium. Therefore, neuroinflammation that is known to 
be present in lysosomal storage diseases[8] could increase brain influx rate and brain 
accumulation of macrophage-derived EVs in case of Batten disease. To this point, we 
demonstrated significant reduction of astrocytosis in the brain of LINCL mice treated with 
EV-TPP1-l, compared to control LINCL mice treated with saline. Overall, EVs nanocarriers 
efficiently accumulate in lysosomes, which are the target organelles for delivery of the 
depleted lysosomal enzymes. This suggests that macrophage-derived EVs may be a 




Recombinant Human TPP1 protein (lot #BIQE03) was a generous gift from BioMarin 
Pharmaceutical Inc. (Novato, CA, USA). GenePORTER 3000 transfection agent was 
purchased from AMS Biotechnology (Milton, Abingdon, UK). Lipophilic fluorescent dyes, 
1,1’-Dioctadecyl-3,3,3’,3’-Tetramethylindodicarbocyanine Perchlorate (DID) and 4’,6-
diamidino-2-phenylindole dihydrochloride (DAPI) were purchased from Invitrogen 
(Carlsbad, CA, USA) and Sigma-Aldrich (St. Louis, MO, USA), respectively. FITC-
conjugated mouse antibodies to LAMP1 were purchased from BD Biosciences (San Diego, 
CA, USA). Cell culture medium and fetal bovine serum (FBS) were purchased from Gibco 
Life Technologies, (Grand Island, NY, USA). Human TPP1/CLN2 ELISA Kit was obtained 
from LifeSpan BioSciences, Inc. (Seattle, WA, USA). TPP1-encoding pDNA (pSJG-JaTl-
hTPP1opt-myc-spa) was a generous gift from Dr. Steven J. Gray (Department of 
Ophthalmology Gene Therapy Center, UNC). TPP1 substrate, AF-AMC and Triton X-100 
were obtained from Sigma-Aldrich. Neuronal growth factor (NGF) was obtained from 
Gemini Bio-Products (West Sacramento, CA, USA).
Cells:
IC21 cell line derived by transformation of normal C57BL/6 mouse peritoneal macrophages 
with SV40, and neuronal PC12 rat adrenal pheochromocytoma cell line were purchased 
from American Type Culture Collection (ATCC, Manassas, VA, USA), and cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) (Hyclone, South Logan, UT, USA) 
supplemented with 10% FBS, and 1% (v/v) of both penicillin and streptomycin. Regarding 
PC12 neuronal cells, they were differentiated with neuronal growth factor (NGF, 100 ng mL
−1) for 4 d before the experiments. Human skin CLN2 fibroblasts deficient in the neuronal 
ceroid-lipofuscinoses (in vitro model of Batten disease), IC21 cells, and PC12 cells were 
grown in an incubator with optimal culture conditions of 37 °C and 5% CO2, and the 
medium was routinely replaced every 2–3 d.
Isolation of EVs:
Conditioned media from IC21 macrophages grown on 75T flasks (20 × 106 cells per flask) 
was collected, and EVs were isolated using gradient centrifugation.[38] In brief, the culture 
supernatants were cleared of cell debris and large vesicles by sequential centrifugation at 
300 g for 10 min, 1000 g for 20 min, and 10 000 g for 30 min, followed by filtration using 
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0.2 μm syringe filters. Then, the cleared sample was spun at 100 000 g for 4 h to pellet the 
EVs, and supernatant was collected. The collected EVs (1011–1012 EV per flask) were 
washed twice with phosphate-buffered saline (PBS). Specifically, the obtained pellet was 
resuspended in high volume PBS (about 10 mL), and then centrifuge it again at 120 000 × g 
for 70 min. Additional step with resuspension in high volume of PBS resulted in dissolution 
of all proteins and small nonvesicular contaminants that were precipitated initially in low 
volume, and allowed us to obtain pure EVs fraction with narrow size distribution. To avoid 
contamination by the FBS-derived EV, FBS was spun at 100 000 g for 2 h to remove EVs 
before the experiment. The recovery of was estimated by measuring the protein 
concentration using the Bradford assay and by Nanoparticle Tracking Analysis (NTA). NTA 
analysis presented in Figure S11 (Supporting Information) showed a narrow size distribution 
with average mean 122.0 ± 2.4 nm, and Mode 105.6 ± 4.6 nm. The obtained EVs fraction 
was re-suspended in PBS (500 μL, 1 mg mL−1 total protein), and characterized for size and 
concentration.
Transfection of Macrophages with TPP1-Encoding pDNA: Manufacture of Therapeutic 
Gene-Encoding pDNA:
The TPP1-encoding pDNA (pSJG-JaTl-hTPP1opt-myc-spa) was expanded in DH5α E. coli 
and then isolated using Qiagen endotoxin-free plasmid Giga-prep kits (Qiagen, Valencia, 
CA, USA) according to the supplier’s protocol. The quantification of the manufactured 
pDNA was accessed by Nanodrop 2000/2000c spectrophotometer (Thermo Scientific) and 
verified by gel electrophoresis (Figure S12, Supporting Information). Totally, 4.5 mg TPP1-
encoding pDNA was manufactured.
Transfection of Parental Cells.
IC21 macrophages were incubated with a mixture of 2 μg mL−1 TPP1-encoding pDNA and 
GenePORTER 3000 in serum free media for four h. Following incubation, the cells were 
washed with PBS and cultured for additional 1–10 d in the complete media containing 10% 
FBS. The transfected cells were collected, and lysed using four freeze-thaw cycles. The 
levels of TPP1 in the cell lysates, EV, and in conditioned media were assessed at different 
time points by TPP1/CLN2 ELISA according to manufacturer’s protocol.
Loading Naive EVs with TPP1:
Two methods for TPP1 incorporation into macrophage-derived EVs were evaluated: the 
sonication of EVs in water bath, or permeabilization of EVs membranes with saponin in the 
presence of TPP1. For drug loading by sonication, 500 μL EVs suspension (1011 particles 
mL−1) were supplemented with 5 μL TPP1 (20 μg/100 μL) and sonicated in water bath at 
room temperature (RT) for 30 min. In case of a saponin treatment, 500 μL EVs suspension 
(1011 particles mL−1) were supplemented with 5 μL TPP1 (20 μg/100μL) and 10 μL saponin 
solution to final concentration 0.4 mg mL−1, and incubate at RT for 30 min. TPP1-loaded 
EVs were purified by size-exclusion chromatography on Sepharose CL 4B (Sigma) (Figure 
S13, Supporting Information). EVs recovery was 90–95%.
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The particle concentration and size were determined by NTA using NanoSight 500 Version 
2.2 (Wiltshire, UK). For the size measurements EVs were dispersed at concentration ≈3 × 
1010 particles mL−1 in phosphate-buffered saline (PBS). The atomic force microscopy 
(AFM) was used to assess the morphology of EVs. Briefly, a drop of the sample was placed 
on a glass slide, dried under an argon flow, and imaged as described earlier.[43] The levels of 
proteins constitutively expressed in EVs (CD63, TSG101, and HSP90) were identified in 
EV-TPP1 formulations by western blot analysis using Wes (ProteinSimple, San Jose, 
California, USA). Protein concentrations were determined using BCA kit (Pierce 
Biotechnology, Rockford, IL, USA). The protein bands were detected with CD63 primary 
monoclonal antibodies (Novus Biologicals, Centennial, CO, USA; 1:1000 dilution, 
#NPB2-67425), or TSG101 monoclonal antibodies (Novus Biologicals, #NPB2-67884), or 
HSP90 monoclonal antibodies (Novus Biologicals, #NPB2-67395), and secondary HRP-
conjugated rabbit antigoat IgG-HRP (Santa Cruse, CA, USA; 1:5000 dilution.
To measure the TPP1 enzymatic activity, 20 μL of EVs or free TPP1 were first added to 60 
μL of activation buffer (50 × 10−3 M acetate, 100 × 10−3 M NaCL, 0.1% Triton X100, 0.4 
mg mL−1 saponin, pH 3.5) and incubated for 1 h at 37 °C. Then, 10 μL of these solutions 
were mixed with 40 μL of the assay buffer (50 × 10–3 M acetate, 100 × 10−3 M NaCL, 0.1% 
Triton X100, pH 5.0) and 50 [L of AF-AMC in the assay buffer (substrate final 
concentration 400 × 10−6 M, EVs final concentration 4.5 × 1011 particles mL−1, or free 
TPP1 final concentration 3 × 10−9 M). The reaction rate was determined by recoding AMC 
fluorescence (λex = 380 nm, λem = 460 nm) using Spectramax for 10 min and employing 
the AMC calibration curve. The same assay was used to determine the enzyme stability 
against proteases degradation. For these studies, 4 μL of proteases from Streptomyces 
Greseus (4 × 10−5 M, Sigma) was added to 400 μL EVs (0.2 × 1010 particles) containing 
TPP1 or free TPP1 (3 × 10−9 M) and incubated for 3 h at 37 °C. Data were expressed as the 
ratio of the residual versus initial TPP1 activities. The initial TPP1 activity was ≈850 pmoles 
min−1 μg−1.
qPCR Analysis:
RNA content in EVs from TPP1-transfected macrophages was determined by reverse 
transcriptase polymerase-chain reaction (RT-PCR). Briefly, the EVs were lysed, treated with 
DNase, reverse transcribed into copy DNA (cDNA) using SuperScript III CellsDirect cDNA 
Synthesis System (Invitrogen, cat # 18080200) according to manufacturer’s protocol, and 
then analyzed by real-time PCR (qPCR). For DNA determination, the EVs were lysed using 
the same protocol as for RNA and then analyzed by qPCR. In both cases qPCR was 
performed on cDNA or lysed EVs, 1 μL each of 20 × 10−6 m forward and reverse primers, 
and 2X PowerUp SYBR Green Master Mix (Applied Biosystems) in a total volume of 25 
μL. qPCR assay was performed using primers specific to GAPDH or the TPP1 gene (the 
forward sequence CTGTCCTCATCACCGCATTT, the reverse sequence 
CGGTTGGAAACGACCCAATA) on a StepOnePlus Real-Time PCR System (Applied 
Biosystems). GAPDH was used as a control gene and RNA isolated from HeLa cells 
(included in CellsDirect cDNA synthesis kit above) was used as a cellular RNA control. For 
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absolute quantification of pDNA, a standard curve was generated using gel-extracted pDNA 
quantified with a Nanodrop (Thermo).
Intracellular Localization of EVs in PC12 Cells by Confocal Microscopy:
To study intracellular localization, IC21 macrophages (20 × 106 cells per flask) were 
cultured for 3 d in DMEM supplemented with 10% FBS, then conditioned media was 
collected, and EVs were isolated by gradient centrifugation as described above. The isolated 
EVs (1010 particles mL−1 total protein) were labeled with a fluorescent dye DID (2 μmol)[33] 
and added to the differentiated neuronal PC12 cells for 1 and 4 h at 37° C. Following 
incubation, the cells were washed with PBS and incubated with FITC-LAMP1 antibodies. 
Then, the staining solution was removed, and cells were washed 2x PBS, fixed, and stained 
for nuclei with DAPI prior to the imaging.[42] The same setup was used to study intracellular 
distribution of EVs in CLN2 cells in vitro. Labeled cells were examined by a confocal 
fluorescence microscopic system ACAS-570 (Meridian Instruments, Okimos, MI) with 
argon ion laser and corresponding filter set. Digital images were obtained using the CCD 
camera (Photometrics) and Adobe Photoshop software. Quantification of immunostaining 
was performed with ImageJ software, utilizing JACoP plugins to calculate Pearson’s 
colocalization coefficients.[50] A comparison was performed on 30–40 sets of images 
acquired with the same optical settings.
LINCL Mice:
LICL mice with mutations of the CLN2 gene encoding a soluble lysosomal enzyme TPP1 
were used as in vivo model of Batten disease.[37] The TETRA-ARMS design (Figure S12A, 
Supporting Information) was used for CLN2 genotyping. Specifically, mutant: 266 bp; wild-
type (WT): 493 bp; and locus: 704 bp bands were visualized to identify mutant KO and 
wild-type mice with inner primers that bind to either the wild-type or mutant (KO) sequence 
(Figure S12B, Supporting Information). Animals were treated in accordance to the 
Principles of Animal Care outlined by National Institutes of Health and approved by the 
Institutional Animal Care and Use Committee of the University of North Carolina at Chapel 
Hill.
Bioimaging and IVIS:
To reduce fluorescence quenching by fur and autofluorescence from solid diet, CLN2 mice 
were shaved and kept on liquid diet for 48 h prior to the imaging studies. Macrophage-
derived naive EVs and EV-TPP1-l were labeled with DiR (Invitrogen) that is a lipophilic, 
near-infrared fluorescent cyanine dye (emission peak of 790) according to manufacturer’s 
instructions. Then, EVs or EV-TPP1-l were administered i.p. CLN2 (one mo. old) mice (2 × 
1011 per mouse in 200 μL saline). For background fluorescence level evaluation, all animals 
were imaged before the injections in the IVIS 200 Series imaging system (Caliper, Xenogen 
Co., Life Sciences). Injected animals were imaged at various time points (1–20 d) post-
treatment. At the endpoint of the experiment (22 d), mice were sacrificed, perfused 
according to the protocol; organs were isolated and imaged by IVIS. Quantitative analysis of 
the levels of fluorescence in the brain was performed using spectral instruments imaging 
ADL Aura software (Biocompare, Tuscon, AZ).
Haney et al. Page 13














Average life span for LINCL mice is about 13 weeks. Therefore, two groups of LINCL mice 
were utilized: 1 week old and 2 months old. The mice were i.p. injected with DiD-labeled 
EVs (obtained as described above) or DID-liposomes (1 × 1010 particles/100 μL per mouse). 
LINCL mice injected with saline were used as controls. Liposomes were prepared as 
described in ref. .[35] According to NTA, the average size of liposomes was 98 ± 4 nm. In 
another experiment, TPP1 was labeled with Alexa 555 according to manufacturer’s protocol, 
and loaded into nonlabeled EVs using sonication method. LINCL mice injected with TPP1 
alone were used as controls. 4 and 24 h later, mice were sacrificed, perfused according to 
standard protocol, the brain slides were washed 3x PBS/Tween 5 min/wash ddH2O, and 
covered using Vectashield Hardset mounting media with DAPI. The images of brain tissues 
were examined by a confocal fluorescence microscopic system ACAS-570 and 
corresponding filter set.
Therapeutic Efficacy of EV-TPP1 in LINCL Mice:
1 week old mice were injected with EV-TPP1-l loaded by sonication in water bath (4.3 × 
1012 particles/150 μL saline per mouse, 15 mg kg−1 TPP1) once a week over 3 weeks. 
LINCL mice as well as wild type littermates were injected with saline as controls. A lifespan 
in all groups was recorded over three months (N = 6).
Immunohistochemical Analyses:
At the end-point (100 d) all treated animals were sacrificed, perfused; brains were removed, 
washed, postfixed, and immunohistochemical analysis was performed in 30 μm thick 
consecutive coronal brain sections.[51] Levels of astrocyte activation were determined by 
fluorescent analysis of GFAP expression. For this purpose, the tissue slices were 
permeabilized with Triton X100, and incubated with primary antibody anti-GFAP (Abcam 
ab7260, 1:500 dilution), and secondary antibody goat antirabbit IgG H+L (Alexa Flour 488, 
Invitrogen A-11008) for 1 h at RT in the dark. Quantification of the fluorescence levels of 
astrocytes was performed as the function of the positive area by ImageJ software (free access 
provided by the National Institute of Health).
Statistical Analysis:
For the all experiments, data were presented as the mean ± SEM. Tests for significant 
differences between the groups in in vitro experiments investigating transfection of 
macrophages were performed using a one-way ANOVA with multiple comparisons (Fisher’s 
pairwise comparisons) using GraphPad Prism 5.0 (GraphPad software, San Diego, CA, 
USA). A standard T-test was performed when only two groups (for example, for the 
evaluation of the expression levels of TPP1 by ELISA) were compared. A minimum p value 
of 0.05 was chosen as the significance level for all tests.
For analysis of statistical significance of therapeutic effects assessed by 
immunohistochemistry for astrocytisis, the endpoint values were compared by group 
(LINCL mice injected with EV-TPP1, or saline, as well as wild type mice injected with 
saline). The endpoint for this assessment was at 90 d. If the differences between the groups 
were significant at the 0.05 level then pairwise tests were conducted using a Bonferroni 
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correction for multiple comparisons. This was then analyzed in the same way as the 
endpoint analysis. The sample size for all in vitro experiments, as well as in vivo therapeutic 
efficacy experiments, was N = 6.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Characterization of EVs isolated from TPP1-transfected macrophages (EV-TPP1-t). TPP1-
transfected macrophages and their EVs display elevated levels of A) TPP1 protein and B) 
enzymatic activity between second and seventh day post-transfection. IC21 macrophages 
were transfected with TPP1-encoding pDNA (2 μg mL−1 pDNA with GenePorter 3K for 4 
h), and (A) TPP1 protein expression and (B) TPP1 enzymatic activity were assessed in the 
parental cells (white bars) and EVs (black bars) using (A) ELISA and (B) a TPP1 substrate, 
AF-AMC (400 μM), respectively. (A) TPP1 protein or (B) activity levels in nontransfected 
cells (dashed line) or EVs secreted by them (solid line) were also recorded. For EVs’ 
activity, the levels are normalized to the number of cells used to isolate these EVs. C) 
Increased stability of TPP1 in EVs (solid line) compared to EV-free TPP1 (dashed line) 
upon incubation with pronase protease from Streptomyces Greseus (4 × 10−5 M). D) Round 
morphology of EVs released by empty-transfected macrophages and TPP1-transfected 
macrophages. E) Quantitative PCR analysis indicated a significant amount of TPP1-
encoding pDNA incorporated in EVs from pretransfected macrophages. (A–C) Statistical 
significance *p < 0.05, or **p < 0.005 compared to TPP1 levels in nontransfected cells or 
(A,B) EVs, or (E) EV-free TPP1.
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Characterization of EV-TPP1-l obtained by TPP1 loading into naïve EVs by either 
sonication or saponin permeabilization: A) TPP1 enzymatic activity and NTA parameters, 
B) morphology by AFM, C) TPP1 release, and D) TPP1 stability in the presence of pronase 
protease from Streptomyces Creseus (4 × 10−5 M) for sonicated EV-TPP1 versus free TPP1. 
(A–D) IC21 macrophage-derived EVs (1011 particles mL−1) were loaded with TPP1 (20 
μg/100 μL) by sonication in water bath, or saponin permeabilization (0.4 mg mL−1). (B) The 
bar: 200 nm. (D) TPP1 activity was measured using AF-AMC (400 × 10−6 M) as a substrate. 
Statistical comparisons of (A) loaded EV-TPP1 versus naive EVs or (D) treated versus 
untreated with pronase TPP1 formulations: *p < 0.05, **p < 0.005 (n = 4).
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Delivery ofTPPl to CLN2 cells with EVs. CLN2 cells were treated with A) either EV-TPP1-t 
(black bars) or EVs from sham macrophages (white bars) for various time intervals, or B,C) 
EV-TPP1-l produced using sonication or saponin permeabilization for 6 h. Following 
treatments, CLN2 cells were lysed and the A,B) TPP1 protein levels were determined by 
ELISA or C) TPP1 activity was measured using AF-AMC (400 × 10−6 M) as a substrate. 
Dashed line—TPP1 protein levels in untreated CLN2 cells (A). Treatments with all EV-
TPP1 formulations resulted in significant increases in the enzyme levels in CLN2 cells. 
Statistical comparisons of (A) EV-TPP1-t treated versus untreated cells or (B,C) cells treated 
with EV-TPP1-l versus empty EVs: *p < 0.05, (n = 4). (A) Difference between EV-TPP1-t 
and empty EV treated cells is not significant.
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EVs target lysosomal compartments in PC12 neuronal cells. The cells were incubated with 
DID-labeled EVs (1010 particles/ml) for A) 1 h or B) 4 h, and then stained with FITC-
LAMP1 antibodies for lysosomes and DAPI for nuclei. Colocalization of EVs (red) and 
lysosomes (green) is manifested in yellow. The bar: 20 μm.
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Biodistribution of EVs in LINCL mice by IVIS. LINCL mice (1 month old) were injected 
with DiR-labeled EVs through i.p. route. Animals were imaged over 20 d by IVIS. A) 
Representative images from N = 4 mice per group (dorsal planes) taken at various time 
points demonstrate prolonged brain accumulation of EVs in LINCL mice. B) Quantitative 
analysis revealed maximal brain accumulation at day 3 with slow decrease of the EVs 
fluorescence levels over 3 weeks. C,D) Postmortem imaging of organs indicate significant 
EV accumulation in the organs decreasing in order: liver > spleen > lungs > kidney > brain.
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Brain distribution of DiD-labeled A) EVs and B) liposomes in knock-out LINCL mice. 
Confocal images showed a strong fluorescence in different brain areas in case of DiD-EV, 
and low, if any, fluorescence in case of DiD-liposomes. 1 week old knock-out mice were 
injected i.p. with DiD-labeled (A) EVs or (B) liposomes (1010 particles/100 μL/mouse). 
Animals were sacrificed 4 h or 24 h after injections and perfused. Brain slides were 
processed and examined by confocal microscopy. Nuclei were stained by DAPI (blue). The 
bar: 50 μm. EVs were isolated from macrophages concomitant media, and labeled with 
fluorescent dye, DiD (red). Liposomes were prepared and labeled with DiD (red).
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EV-TPP1-l treatment increased lifespan in LINCL mice. 1 week old LINCL mice were 
injected i.p. with EV-TPP1-l three times every week (crosses) or EVs alone (circles). Control 
LINCL mice (diamonds) and wild type animals (triangles) were injected with saline. A 
survival of treated animals was recoded over three months. A significantly greater lifespan 
(p < 0.05) was demonstrated in EV-TPP1-l treatment group compared to CLN2 mice treated 
with saline (N = 6).
Haney et al. Page 24














EV-TPP1-l treatment decreases astrocytosis in LINCL mice. 1 week old LINCL mice were 
injected i.p. with A) saline, or B) EV-TPP1-l once per week, three weeks. C) Control wild 
type animals were injected with saline. Animals were sacrificed at day 100, and brain slides 
were stained with antibody to GFAP, a marker for activated astrocytes. The obtained 
confocal images (A–C) and quantification of astrocyte staining (D) indicate significant 
decreases in astrocytosis in the brain of LINCL mice upon EV-TPP1-l treatment (B) 
compared to LINCL mice treated with saline (A). *p < 0.05. The bar: 100 μm.
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